Cabot CORP

Cabot Corporation has announced the pricing of a $350 million offering of 4.950% notes due 2029, with an expected closing date of August 21, 2026.

Cabot Corporation reported third quarter fiscal year 2026 results with diluted EPS of $0.12 and adjusted EPS of $1.67, driven by strong Performance Chemicals segment performance, while facing challenges in Reinforcement Materials.

Cabot Corporation announced a planned leadership transition, with President and CEO Sean Keohane retiring effective September 30, 2026, and Erica McLaughlin appointed as his successor.

Cabot Corporation has entered into a new $1.3 billion unsecured revolving credit agreement, replacing its previous credit lines and providing flexibility for general corporate purposes.

Cabot Corporation announced its second quarter fiscal year 2026 results, reporting diluted EPS of $1.27 and adjusted EPS of $1.61, while also increasing its quarterly dividend by 5%.

Cabot Corporation's annual meeting saw stockholders elect three directors, approve executive compensation, and ratify Deloitte & Touche LLP as auditors.

Cabot Corporation reports a substantial decline in Q3 net income and EPS, primarily attributed to increased restructuring expenses and reduced performance in its Reinforcement Materials segment.

Cabot Corporation reported a decline in first-quarter net income and sales, driven by lower volumes and pricing in its Reinforcement Materials segment, despite growth in Performance Chemicals EBIT.

Cabot Corporation reported a decline in third-quarter net income and sales, primarily driven by reduced volumes and less favorable pricing in its Reinforcement Materials segment, despite improved nine-month results due to reduced foreign exchange losses.

Cabot Corporation's Q2 fiscal year 2025 saw a decrease in net sales but an increase in net income, driven by Performance Chemicals' strong performance offsetting lower Reinforcement Materials volumes.

Cabot Corporation's Q1 2025 net income attributable to Cabot Corporation increased to $93 million, up from $50 million in Q1 2024, driven by lower foreign exchange losses and higher segment earnings.

Cabot Corporation's Q3 2024 earnings increased significantly year-over-year, driven by higher volumes in both Reinforcement Materials and Performance Chemicals segments.

Cabot Corporation reports a mixed fiscal year 2025 with growth in its Performance Chemicals segment offset by declines in Reinforcement Materials and a higher income tax provision, leading to reduced net income and EPS.

Cabot Corporation's annual 10-K filing highlights its strategic focus on growth through innovation and sustainability, while navigating environmental regulations and global market dynamics.

Sean D Keohane, President and CEO and a Director of Cabot Corp, sold 91,923 shares of common stock on August 7, 2026 for $86.41 per share.

Cabot Corporation director Raffiq Nathoo has reported a transaction involving phantom stock units, with settlement details outlined.

Cabot Corporation's President and CEO, Sean D. Keohane, reported the acquisition of 83.6823 phantom stock units under the company's supplemental 401(k) plan.

Lisa M. Dumont of Cabot Corp reported a transaction involving phantom stock units, increasing her beneficial ownership.

Cabot Corporation Director Douglas G. Del Grosso acquired phantom stock units under the company's Non-Employee Director's Deferral Plan.

Cabot Corporation's SVP and General Counsel, Karen A. Kalita, reported a transaction involving phantom stock units.

Cabot Corporation announces its 2026 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation, and auditor ratification.

Cabot Corporation announces its 2026 Annual Meeting of Stockholders to be held virtually on March 12, 2026, focusing on director elections, executive compensation advisory vote, and auditor ratification.

Cabot Corporation has announced its 2025 Annual Meeting of Shareholders, scheduled for March 13, 2025, and provided details on how shareholders can vote on key proposals.

Cabot Corporation has announced its 2025 Annual Meeting of Stockholders, scheduled for March 13, 2025, where shareholders will vote on director elections, executive compensation, a new incentive plan, and auditor ratification.

A Schedule 13G filing reveals that American Century entities and Stowers Institute for Medical Research collectively hold a significant stake in Cabot Corporation.

Vanguard Capital Management has reported beneficial ownership of 5.22% of Cabot Corporation's common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 3,175,315 shares, representing 6.08% of Cabot Corporation's common stock, as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Cabot Corp following an internal realignment.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a passive beneficial ownership of 7.8% of Cabot Corporation's common stock as of March 31, 2025.